

**MOSAIC FORUM**  
**Washington DC**  
**June 30 & July 1 2022**

**PROGRAM**

**Thursday 30 June 2022**

**Introduction 09:00-09:15**

**Session 1: Epidemiology**      Chairs: XX

<b>09:15 – 09:25</b>	<b>Burden of cardiorenal disease in NAFLD patients</b>
<b>09:25 – 09:35</b>	<b>Burden of liver related comorbidities in cardiovascular disease</b>
<b>09:35 – 09:45</b>	<b>Burden of cardiac and liver disease in patients with CKD</b>
<b>09:45 – 09:55</b>	<b>Discuss prevalence and incidence and cost of care- point is to highlight everything happening in same patient</b>
<b>09:55 – 10:00</b>	<b>Regulatory viewpoint</b>
<b>10:00 – 10:05</b>	<b>Industry viewpoint</b>
<b>10:05 – 10:10</b>	<b>Patient viewpoint</b>
<b>10:10 – 10:30</b>	<b>Coffee break</b>

**Session 2: Disease Mechanisms**      Chairs: XX

<b>10:30 – 10:40</b>	<b>Mechanisms of atherosclerosis acceleration due to NAFLD</b>
<b>10:40 – 10:50</b>	<b>Cholesterol metabolism</b>
<b>10:50 – 11:00</b>	<b>Inflammatory signals and macrophage biology</b>
<b>11:00 – 11:10</b>	<b>Liver-artery cross-talk</b>
<b>11:10 – 11:20</b>	<b>Mechanisms of myocardial dysfunction in NAFLD</b>
<b>11:20 – 11:30</b>	<b>Metabolic milieu</b>
<b>11:30 – 11:40</b>	<b>Mechanistic data on acceleration of myocardial dysfunction due to liver disease</b>
<b>11:40 – 11:50</b>	<b>QTc and arrhythmogenesis- role of metabo-inflammation and fibrosis</b>
<b>11:50 – 11:55</b>	<b>Regulatory viewpoint</b>
<b>11:55 – 12:00</b>	<b>Industry viewpoint</b>
<b>12:00 – 12:05</b>	<b>Patient viewpoint</b>
<b>12:05-13:15</b>	<b>Lunch break</b>

**Session 3: Common Biology**      Chairs: XX

<b>13:15 – 13:25</b>	<b>Role of the metabolic milieu for liver and cardiac disease (endocrine speaker)</b>
<b>13:25 – 13:35</b>	<b>Role of systemic inflammatory state in cardiac, renal and liver involvement in metabolic syndrome (cardiology speaker)</b>
<b>13:35 – 13:45</b>	<b>Systemic drivers of pro-fibrogenic state in Metabolic syndrome (liver speaker)</b>
<b>13:45 – 13:50</b>	<b>Regulatory viewpoint</b>
<b>13:50 – 13:55</b>	<b>Industry viewpoint</b>

**MOSAIC FORUM**  
**Washington DC**  
**June 30 & July 1 2022**

<b>13</b>	<b>Patient viewpoint</b>
<b>:55 – 14:00</b>	
<b>Session 4: Study Populations</b>	<b>Chairs: XX</b>
<b>14:00 – 14:10</b>	<b>Cardiac characterization in NAFLD trials</b>
<b>14:10 – 14:20</b>	<b>Renal disease characterization in NAFLD trials</b>
<b>14:20 – 14:30</b>	<b>NAFLD characterization in cardiovascular trials</b>
<b>14:30 – 14:35</b>	<b>Regulatory viewpoint</b>
<b>14:35 – 14:40</b>	<b>Industry viewpoint</b>
<b>14:40 – 14:45</b>	<b>Patient viewpoint</b>
<b>Session 5: Endpoints</b>	<b>Chairs: XX</b>
<b>14:45 – 14:55</b>	<b>Cardiac endpoints in NAFLD outcome trials</b>
<b>14:55 – 15:05</b>	<b>Renal endpoints in NAFLD outcome trials</b>
<b>15:05 – 15:15</b>	<b>Liver endpoints in cardio-renal trials</b>
<b>15:15 – 15:20</b>	<b>Regulatory viewpoint</b>
<b>15:20 – 15:25</b>	<b>Industry viewpoint</b>
<b>15:25 – 15:30</b>	<b>Patient viewpoint</b>
<b>15:30 – 16:00</b>	<b>Coffee break</b>
<b>Session 6: Trial Innovations</b>	<b>Chairs: XX</b>
<b>16:00 – 16:10</b>	<b>Pragmatic trials</b>
<b>16:10 – 16:20</b>	<b>Minorities in CVD, CKD and NASH trials</b>
<b>16:20 – 16:30</b>	<b>Use of hierarchical endpoints</b>
<b>16:30 – 16:40</b>	<b>Use of technology to complete long term outcome trials</b>
<b>16:40 – 16:50</b>	<b>External validity</b>
<b>16:50 – 17:00</b>	<b>Best practices to keep patients in the trial in the context of long</b>
<b>17:00 – 17:05</b>	<b>Regulatory viewpoint</b>
<b>17:05 – 17:10</b>	<b>Industry viewpoint</b>
<b>17:10 – 17:15</b>	<b>Patient viewpoint</b>
<b>WRAP UP DAY 1</b>	
<b>17:30</b>	<b>Transfer back to hotel</b>
<b>19:00</b>	<b>Dinner</b>

**Friday 1 July 2022**

**Session 7: Use of NITS for efficacy and safety assessment- circulating**      **Chairs: XX**

**MOSAIC FORUM**  
**Washington DC**  
**June 30 & July 1 2022**

---

<b><i>biomarkers</i></b>	
<b>09:00 – 09:10</b>	<b>Cardiac biomarkers and NITs</b>
<b>09:10 – 09:20</b>	<b>Liver biomarkers and NITs</b>
<b>09:20 – 09:30</b>	<b>Renal biomarkers and NITs</b>
<b>09:30 – 09:35</b>	<b>Regulatory viewpoint</b>
<b>09:35 – 09:40</b>	<b>Industry viewpoint</b>
<b>09:40 – 09:45</b>	<b>Patient viewpoint</b>
<b><i>Session 8: Use of NITs for efficacy and safety assessment- Imaging</i></b>	<b>Chairs: XX</b>
<b>09:45 – 09:55</b>	<b>Cardiac Imaging based assessment of NAFLD</b>
<b>09:55 – 10:05</b>	<b>Can atherosclerotic burden be quantified and is it useful?</b>
<b>10:05 – 10:15</b>	<b>Imaging based assessment of NAFLD</b>
<b>10:15 – 10:20</b>	<b>Regulatory viewpoint</b>
<b>10:20 – 10:25</b>	<b>Industry viewpoint</b>
<b>10:25 – 10:30</b>	<b>Patient viewpoint</b>
<b><i>Session 9: Therapeutics</i></b>	<b>Chairs: XX</b>
<b>10:30 – 10:40</b>	<b>Reviewing the therapeutic landscape for CV disease</b>
<b>10:40 – 10:50</b>	<b>Reviewing the therapeutic landscape for type 2 diabetes</b>
<b>10:50 – 11:00</b>	<b>Reviewing the therapeutic landscape in NAFLD</b>
<b>11:00 – 11:10</b>	<b>Reviewing the therapeutic landscape for CKD</b>
<b>11:10 – 11:15</b>	<b>Regulatory viewpoint</b>
<b>11:15 – 11:20</b>	<b>Industry viewpoint</b>
<b>11:20 – 11:25</b>	<b>Patient viewpoint</b>
<b>11:25 – 12:00</b>	<b>Coffee break</b>
<b><i>Session 10: Breakout sessions and report back</i></b>	<b>Chairs: XX</b>
<b>13:00</b>	<b>Finger food buffet lunch and transfer back to airport</b>

---